EUVIMEDEUVIMED entdecken
Crossref

Efficacy, Confounders and Safety of the Preserflo Microshunt

Cemre Altas, Thomas A Fuchsluger, Tobias Brockmann, Anna Graumüller, Marcus Walckling

Klinische Monatsblätter für Augenheilkunde · 01.09.2024 · 241 (09) · 1048-1056

DOI: 10.1055/a-2325-9286 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Klinische Monatsblätter für Augenheilkunde, erschienen am 01.09.2024. Verfasst von Cemre Altas und 4 weiteren Autor:innen. Beteiligte Einrichtung: Klinik und Poliklinik für Augenheilkunde, Universitätsmedizin Rostock, Deutschland. Hauptthemen laut MEDLINE: Glaucoma, Open-Angle. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glaucoma is a leading cause of blindness worldwide. We evaluated the efficacy, confounders, and safety of the Preserflo Microshunt over a one-year follow-up period.

Methods

In this retrospective monocentric study, 111 eyes were evaluated. 83 eyes had primary open angle glaucoma, and 28 eyes secondary open angle glaucoma. Intraocular pressure (IOP), visual acuity, number of glaucoma medications, complications, and reoperations were evaluated postoperatively, at 1, 3, 6, 9, and 12 months. The influence of age, sex, type of glaucoma, previous surgery and lens status was also analysed. Bleb revision was indicated if corrected IOP exceeded 18 mmHg.

Results

Intraocular pressure significantly decreased from 24.50 ± 8.94 to 14.62 ± 4.86 mmHg (4 – 32 mmHg; p < 0.001), the number of medications from 3.19 ± 1.14 to 0.98 ± 1.39 (0 – 4; p < 0.001). Confounders of interest did not affect efficacy. Bleb revision was performed in 22.5% of eyes and a cyclophotocoagulation was performed in 9.9% of eyes. Complete surgical success (IOP ≤ 17 mmHg, IOP reduction ≥ 20%, without medication) was achieved in 36.9% (n = 41) and qualified success (with medication) in 51.4% (n = 57) of eyes. Transient hypotension (≤ 5 mmHg) occurred in 19.8% after primary implantation and in 1.8% after bleb revision (duration ≤ 3 months).

Conclusion

To date, the Preserflo Microshunt has demonstrated good efficacy and a low risk profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glaucoma, Open-AngleHumansFemaleMaleMiddle AgedRetrospective StudiesTreatment OutcomeAgedAdultAged, 80 and overIntraocular PressureVisual AcuityPostoperative ComplicationsGlaucoma Drainage ImplantsRisk FactorsReoperation

Autor:innen und Institutionen

  • Klinik und Poliklinik für Augenheilkunde, Universitätsmedizin Rostock, Deutschland.
  • Hals-Nasen-Ohrenheilkunde, Universitätsmedizin Rostock, Deutschland.

Zitieren

APA

Altas, C., Fuchsluger, T. A., Brockmann, T., Graumüller, A., & Walckling, M. (2024). Efficacy, Confounders and Safety of the Preserflo Microshunt. Klinische Monatsblätter für Augenheilkunde, 241(09), 1048-1056. https://doi.org/10.1055/a-2325-9286

Vancouver

Altas C, Fuchsluger TA, Brockmann T, Graumüller A, Walckling M. Efficacy, Confounders and Safety of the Preserflo Microshunt. Klinische Monatsblätter für Augenheilkunde. 2024;241(09):1048-1056. doi:10.1055/a-2325-9286

BibTeX
@article{Altas2024,
  author = {Altas, Cemre and Fuchsluger, Thomas A and Brockmann, Tobias and Graumüller, Anna and Walckling, Marcus},
  title = {Efficacy, Confounders and Safety of the Preserflo Microshunt},
  journal = {Klinische Monatsblätter für Augenheilkunde},
  year = {2024},
  volume = {241},
  number = {09},
  pages = {1048--1056},
  doi = {10.1055/a-2325-9286}
}
Kostenlos starten →